PNEUMOCOCCAL MENINGITIS IN FINLAND AND POLAND- COMPARISON OF TRENDS AND SEROTYPE DISTRIBUTION IN A COUNTRY WITH AND WITHOUT UNIVERSAL CHILDHOOD CONJUGATE PNEUMOCOCCAL VACCINATION

2016 ◽  
Author(s):  
Aleksandra Polkowska
Keyword(s):  
Pneumococcal Meningitis ◽  
Pneumococcal Vaccination ◽  
Serotype Distribution

scholarly journals Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden

2016 ◽  
Vol 47 (4) ◽  
pp. 1208-1218 ◽  
Author(s):  
Ilias Galanis ◽  
Ann Lindstrand ◽  
Jessica Darenberg ◽  
Sarah Browall ◽  
Priyanka Nannapaneni ◽  
...  
Keyword(s):  
Invasive Pneumococcal Disease ◽  
Pneumococcal Disease ◽  
Pneumococcal Vaccination ◽  
Clinical Information ◽  
Immunisation Programme ◽  
The Elderly ◽  
Older Children ◽  
Serotype Distribution ◽  
Vaccine Introduction ◽  
Herd Protection

The effects of pneumococcal conjugated vaccines (PCVs) need to be investigated. In Stockholm County, Sweden, PCV7 was introduced in the childhood immunisation programme in 2007 and changed to PCV13 in 2010.Over 90% of all invasive isolates during 2005–2014 (n=2336) and carriage isolates, 260 before and 647 after vaccine introduction, were characterised by serotyping, molecular typing and antibiotic susceptibility, and serotype diversity was calculated. Clinical information was collected for children and adults with invasive pneumococcal disease (IPD).The IPD incidence decreased post-PCV7, but not post-PCV13, in vaccinated children. Beneficial herd effects were seen in older children and adults, but not in the elderly. The herd protection was more pronounced post-PCV7 than post-PCV13. PCV7 serotypes decreased. IPD caused by PCV13 serotypes 3 and 19A increased post-PCV7. Post-PCV13, serotypes 6A and 19A, but not serotype 3, decreased. The serotype distribution changed in carriage and IPD to nonvaccine types, also in nonvaccinated populations. Expansion of non-PCV13 serotypes was largest following PCV13 introduction. Serotype diversity increased and nonvaccine clones emerged, such as CC433 (serotype 22F) in IPD and CC62 (serotype 11A) in carriage. In young children, meningitis, septicaemia and severe rhinosinusitis, but not bacteraemic pneumonia, decreased.Pneumococcal vaccination leads to expansion of new or minor serotypes/clones, also in nonvaccinated populations.

scholarly journals Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006

2008 ◽  
Vol 13 (35) ◽  
Author(s):  
A Lepoutre ◽  
E Varon ◽  
S Georges ◽  
L Gutmann ◽  
D Lévy-Bruhl
Keyword(s):  
Pneumococcal Meningitis ◽  
Age Groups ◽  
Pneumococcal Vaccination ◽  
Early Observation ◽  
Older Children ◽  
Vaccine Serotypes ◽  
Time Period ◽  
Laboratory Surveillance ◽  
Pneumococcal Bacteraemia ◽  
The Impact

Vaccination with the 7-valent pneumococcal conjugate vaccine (PCV) has been recommended in France since 2003 for children under the age of two years who are at risk due to medical or living conditions. From 2006, the recommendation has been extended to all children under two years. The impact of PCV introduction on the incidence of pneumococcal meningitis and bacteraemia and on the serotype distribution in French children and other age-groups was assessed using laboratory surveillance data. The coverage with three doses of PCV was 44% in children aged 6-12 months in 2006. From 2001/2002 to 2006, the incidence of pneumococcal meningitis decreased from 8.0 to 6.0 cases per 100,000, and the incidence of pneumococcal bacteraemia decreased from 21.8 to 17.5 cases per 100,000 in children under the age of two years. For the vaccine strains, the incidence of pneumococcal meningitis and bacteraemia decreased from 20,4 to 6.0 cases per 100,000, while the incidence of pneumococcal meningitis and bacteraemia due to non-vaccine strains increased from 9.4 to 17.5 cases per 100,000 in this time period. The incidence in older children and adults did not decrease. Further expansion of PCV coverage is expected to increase the impact of the vaccination in both children and adults. However, the fact that cases caused by vaccine serotypes have been partially substituted by cases of non-vaccine serotypes is likely to reduce the overall benefit of PCV in France, should this early observation be confirmed in the future.

scholarly journals Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project

2021 ◽  
Vol 9 (4) ◽  
pp. 738 ◽  
Author(s):  
Maria Garcia Quesada ◽  
Yangyupei Yang ◽  
Julia Bennett ◽  
Kyla Hayford ◽  
Scott Zeger ◽  
...  
Keyword(s):  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Meningitis ◽  
Additional Data ◽  
Serotype Distribution ◽  
Investigational Product ◽  
Vaccination Programs ◽  
Meningitis Belt ◽  
Serotype Replacement ◽  
Primary Series ◽  
Pneumococcal Serotype

Pneumococcal conjugate vaccine (PCV) introduction has reduced pneumococcal meningitis incidence. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project described the serotype distribution of remaining pneumococcal meningitis in countries using PCV10/13 for least 5–7 years with primary series uptake above 70%. The distribution was estimated using a multinomial Dirichlet regression model, stratified by PCV product and age. In PCV10-using sites (N = 8; cases = 1141), PCV10 types caused 5% of cases <5 years of age and 15% among ≥5 years; the top serotypes were 19A, 6C, and 3, together causing 42% of cases <5 years and 37% ≥5 years. In PCV13-using sites (N = 32; cases = 4503), PCV13 types caused 14% in <5 and 26% in ≥5 years; 4% and 13%, respectively, were serotype 3. Among the top serotypes are five (15BC, 8, 12F, 10A, and 22F) included in higher-valency PCVs under evaluation. Other top serotypes (24F, 23B, and 23A) are not in any known investigational product. In countries with mature vaccination programs, the proportion of pneumococcal meningitis caused by vaccine-in-use serotypes is lower (≤26% across all ages) than pre-PCV (≥70% in children). Higher-valency PCVs under evaluation target over half of remaining pneumococcal meningitis cases, but questions remain regarding generalizability to the African meningitis belt where additional data are needed.

scholarly journals Pneumococcal meningitis: clinical and epidemiological features, and circulating pathogens’ serotype distribution in Krasnoyarsk territory

2020 ◽  
Vol 12 (2) ◽  
pp. 43-49
Author(s):  
G. P. Martynova ◽  
I. N. Protasova ◽  
I. A. Kutisсhheva ◽  
O. P. Ovchinnikova ◽  
N. A. Rokatansky ◽  
...  
Keyword(s):  
Pneumococcal Meningitis ◽  
Serotype Distribution ◽  
Epidemiological Features

Pediatric Acute Otitis Media in the Era of Pneumococcal Vaccination

2017 ◽  
Vol 156 (5) ◽  
pp. 938-945 ◽  
Author(s):  
Kareem O. Tawfik ◽  
Stacey L. Ishman ◽  
Mekibib Altaye ◽  
Jareen Meinzen-Derr ◽  
Daniel I. Choo
Keyword(s):  
Hospital Admission ◽  
Otitis Media ◽  
Pneumococcal Meningitis ◽  
Acute Otitis Media ◽  
Pneumococcal Vaccination ◽  
Acute Mastoiditis ◽  
Suppurative Otitis Media ◽  
Admission Rates ◽  
Annual Prevalence ◽  
Admission Prevalence

Objectives (1) Describe longitudinal trends in annual prevalence of hospital admission for pediatric acute otitis media (AOM) and complications of AOM (CAOM) since introduction of pneumococcal vaccination in 2000 and (2) describe the longitudinal trend of prevalence of hospital admission for pneumococcal meningitis in children with AOM-related diagnoses in the postvaccination era. Study Design Retrospective analysis of Kids’ Inpatient Database from 2000 to 2012. Setting Community, nonrehabilitation hospitals. Subjects and Methods To determine annual prevalence of admission for AOM/CAOM, nationally weighted frequencies of children aged <21 years with acute suppurative otitis media, acute mastoiditis, suppurative labyrinthitis, and/or acute petrositis were collected. The frequency of coexisting pneumococcal meningitis diagnoses among these patients was also collected. Trend analysis of prevalences of admission for AOM/CAOM and for pneumococcal meningitis occurring in the setting of AOM/CAOM from 2000 to 2012 was performed. Results Between 2000 and 2012, annual prevalence of admission for AOM/CAOM decreased from 3.956 to 2.618 per 100,000 persons ( P < .0001) (relative risk reduction 34%). Declines in admission prevalence were most pronounced in children <1 year of age (from 22.647 to 8.715 per 100,000 persons between 2000 and 2012, P < .0001) and 1 to 2 years of age (from 13.652 to 5.554 per 100,000 persons between 2000 and 2012, P < .0001). For all ages, the admission prevalence for pneumococcal meningitis and concomitant AOM/CAOM decreased (from 1.760 to 0.717 per 1,000,000 persons, P < .0001) over the study period. Conclusions The prevalence of hospital admission for pediatric AOM/CAOM has declined since the advent of pneumococcal vaccination. Admission rates for pneumococcal meningitis with AOM/CAOM have similarly declined.

Sign in / Sign up

Export Citation Format

Share Document